Provectus Biopharmaceuticals, Inc. (NYSE MKT:PVCT, www.pvct.com),
a clinical-stage oncology and dermatology biopharmaceutical company
("Provectus" or “The Company”), announced today that the abstract for an
upcoming poster presentation of data on intralesional PV-10 and
co-inhibitory blockade and mechanisms of T cell mediated immunity in a
melanoma model is now publicly available. The poster is scheduled for
presentation at the American Association for Cancer Research (AACR)
Annual Meeting 2016, being held at the Ernest N. Morial Convention
Center in New Orleans, Louisiana, from April 16-20, 2016.
To view the abstract (number 4978), please visit: http://www.abstractsonline.com/4978.
About the American Association for Cancer Research
The mission of the American Association for Cancer Research is to
prevent and cure cancer through research, education, communication, and
collaboration. Through its programs and services, the AACR fosters
research in cancer and related biomedical science; accelerates the
dissemination of new research findings among scientists and others
dedicated to the conquest of cancer; promotes science education and
training; and advances the understanding of cancer etiology, prevention,
diagnosis, and treatment throughout the world.
The AACR is the oldest and largest scientific organization in the world
focused on every aspect of high-quality, innovative cancer research. Its
reputation for scientific breadth and excellence attract the premier
researchers in the field. The programs and services of the AACR foster
the exchange of knowledge and new ideas among scientists dedicated to
cancer research, provide training opportunities for the next generation
of cancer researchers, and increase public understanding of cancer.
About Provectus Biopharmaceuticals, Inc.
Provectus Biopharmaceuticals, Inc., specializes in developing oncology
and dermatology therapies. PV-10, its novel investigational drug for
cancer, is designed for injection into solid tumors (intralesional
administration), thereby reducing potential for systemic side effects.
Its oncology focus is on melanoma, breast cancer and cancers of the
liver. The Company has received orphan drug designations from the FDA
for its melanoma and hepatocellular carcinoma indications. PH-10, its
topical investigational drug for dermatology, is undergoing clinical
testing for psoriasis and atopic dermatitis. Provectus has completed
Phase 2 trials of PV-10 as a therapy for metastatic melanoma, and of
PH-10 as a topical treatment for atopic dermatitis and psoriasis.
Information about these and the Company's other clinical trials can be
found at the NIH registry, www.clinicaltrials.gov.
For additional information about Provectus, please visit the Company's
website at www.pvct.com or
contact Porter, LeVay & Rose, Inc.
FORWARD-LOOKING STATEMENTS: This release contains "forward-looking
statements" as defined under U.S. federal securities laws. These
statements reflect management's current knowledge, assumptions, beliefs,
estimates, and expectations and express management's current views of
future performance, results, and trends and may be identified by their
use of terms such as "anticipate," "believe," "could," "estimate,"
"expect," "intend," "may," "plan," "predict," "project," "will," and
other similar terms. Forward-looking statements are subject to a number
of risks and uncertainties that could cause our actual results to
materially differ from those described in the forward-looking
statements. Readers should not place undue reliance on forward-looking
statements. Such statements are made as of the date hereof, and we
undertake no obligation to update such statements after this date.
Risks and uncertainties that could cause our actual results to
materially differ from those described in forward-looking statements
include those discussed in our filings with the Securities and Exchange
Commission (including those described in Item 1A of our Annual Report on
Form 10-K for the year ended December 31, 2014) and the following:
-
our determination, based on guidance from the FDA, whether to proceed
with or without a partner with the fully enrolled phase 3 trial of
PV-10 to treat locally advanced cutaneous melanoma and the costs
associated with such a trial if it is necessary to complete (versus
interim data alone);
-
our determination whether to license PV-10, our investigational drug
product for melanoma and other solid tumors such as cancers of the
liver, if such licensure is appropriate considering the timing and
structure of such a license, or to commercialize PV-10 on our own to
treat melanoma and other solid tumors such as cancers of the liver;
-
our ability to license PH-10, our investigational drug product for
dermatology, on the basis of our phase 2 atopic dermatitis and
psoriasis results, which are in the process of being further developed
in conjunction with mechanism of action studies; and
-
our ability to raise additional capital if we determine to
commercialize PV-10 and/or PH-10 on our own, although our expectation
is to be acquired by a prospective pharmaceutical or biotech concern
prior to commercialization.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160318005085/en/
Copyright Business Wire 2016